218. Alport syndrome Clinical trials / Disease details
Clinical trials : 26 / Drugs : 33 - (DrugBank : 13) / Drug target genes : 6 - Drug target pathways : 29
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05267262 (ClinicalTrials.gov) | March 15, 2022 | 23/2/2022 | Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis | A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in AS Patients With Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients With Primary Steroid-Resistant FSGC | Alport Syndrome;Focal Segmental Glomerulosclerosis | Drug: R3R01 | River 3 Renal Corp. | IQVIA Biotech | Not yet recruiting | 12 Years | N/A | All | 50 | Phase 2 | NULL |